Drug
Mipomersen
Mipomersen: highest development phase Phase 3, developed by United Therapeutics. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| mipomersen sodium NCT00706849 | Phase 3 | Heterozygous Familial Hypercholesterolemia |
| Mipomersen sodium NCT00770146 | Phase 3 | Hypercholesterolemia |
| mipomersen sodium NCT01090661 | Phase 1 | Healthy |
| mipomersen NCT01299298 | Phase 1 | Healthy Volunteer |
Latest
No recent events.
Follow Mipomersen on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.